Puma Biotechnology, Inc.
PBYI
$5.25
$0.030.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.37% | 5.12% | -18.15% | 43.53% | -13.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.37% | 5.12% | -18.15% | 43.53% | -13.72% |
| Cost of Revenue | 15.42% | -1.60% | -42.77% | 119.04% | -10.11% |
| Gross Profit | 10.19% | 7.30% | -5.64% | 20.11% | -14.72% |
| SG&A Expenses | -27.73% | -19.06% | -15.02% | -26.24% | 2.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.03% | -8.77% | -19.46% | 23.00% | -0.83% |
| Operating Income | 404.54% | 273.29% | -13.34% | 157.18% | -144.54% |
| Income Before Tax | 248.52% | 171.10% | -4.42% | 242.95% | -279.46% |
| Income Tax Expenses | -17.99% | 33.18% | -1,418.47% | 36.62% | 102.14% |
| Earnings from Continuing Operations | 229.28% | 161.77% | 57.36% | 250.53% | -313.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 229.28% | 161.77% | 57.36% | 250.53% | -313.03% |
| EBIT | 404.54% | 273.29% | -13.34% | 157.18% | -144.54% |
| EBITDA | 1,189.30% | 1,033.78% | -11.50% | 117.76% | -90.62% |
| EPS Basic | 225.59% | 160.06% | 52.58% | 239.84% | -306.15% |
| Normalized Basic EPS | 244.32% | 169.13% | -11.63% | 232.66% | -273.79% |
| EPS Diluted | 225.59% | 160.00% | 58.48% | 241.67% | -306.15% |
| Normalized Diluted EPS | 243.02% | 168.62% | -11.39% | 233.63% | -275.49% |
| Average Basic Shares Outstanding | 2.92% | 2.92% | 3.14% | 3.13% | 3.28% |
| Average Diluted Shares Outstanding | 3.84% | 3.56% | 2.85% | 2.83% | 2.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |